Pharmaceutical company Boehringer Ingelheim and ZEISS Medical Technology have announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases.
The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs.
The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging ZEISS Medical Technology’s cloudconnected devices and artificial intelligence-assisted analysis of its extensive image data sets.
This will provide a basis for clinical studies for development of more personalised and precise treatments of early stages of chronic retinal disease as well as earlier detection and prediction capabilities to preserve vision through new treatment pathways.
“At ZEISS, we have long understood that where collaboration thrives, innovation emerges,” said Euan S. Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology.
Boehringer Ingelheim’s Head of Retinal Health, Dr Ulrike GraefeMody said the partnership with ZEISS would allow the development of “precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs”.
“It is part of our commitment to champion early detection and treatment and will contribute to transforming the lives of people with serious eye disease,” Dr Graefe-Mody said.
